Entering text into the input field will update the search result below

Gyroscope Therapeutics Seeks $142 Million In U.S. IPO

May 04, 2021 5:26 AM ETGyroscope Therapeutics Holdings plc (VISN)


  • Gyroscope Therapeutics has filed to raise $142 million in an IPO.
  • The firm is developing gene-based treatments for age-related macular degeneration.
  • VISN has produced intriguing early stage results, but we don't know the subset patient market size and the U.S. FDA is notoriously slow in approving gene-based therapies.
  • I'll watch the IPO from the sidelines.
  • Looking for more investing ideas like this one? Get them exclusively at IPO Edge. Learn More »
Scientists studying a virus ,looking through microscope
Photo by Nastasic/E+ via Getty Images

Quick Take

Gyroscope Therapeutics Holdings plc (NASDAQ:VISN) has filed to raise $142 million in an IPO of its American Depositary Shares representing underlying ordinary shares, according to an F-1/A registration statement.

The firm is a clinical stage biopharma developing treatments

Gain Insight and actionable information on U.S. IPOs with IPO Edge research.

Members of IPO Edge get the latest IPO research, news, and industry analysis.

Get started with a free trial!

This article was written by

Donovan Jones profile picture

Donovan Jones is a research specialist with 15 years of experience identifying opportunities for IPOs and software companies.

He also leads the investing group

IPO Edge

which offers: actionable information on growth stocks through first look S-1 filings, previews on upcoming IPOs, an IPO calendar for tracking what’s on the horizon, a database of U.S. IPOs, and a guide to IPO investing to walk you through the entire IPO lifecycle - from filing to listing to quiet period and lockup expiration dates.

Learn more


Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You


Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

More on VISN

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.